Astragaloside IV suppresses inflammatory response via suppression of NF-κB, and MAPK signalling in human bronchial epithelial cells

Context: Astragaloside IV isolated from Astragalus membranaceus (Fisch.), which was reported to have anti-tumor, anti-asthma, and suppressed cigarette smoke-induced lung inflammation in mice. Objectives: This study investigated whether astragaloside IV reduced the expression of inflammatory mediators and oxidative stress in BEAS-2B cells. Methods: BEAS-2B cells treated with astragaloside IV, and then stimulated with TNF-alpha or TNF-alpha/IL-4. The levels of cytokine and chemokine were analysed with ELISA and real-time PCR. Results: Astragaloside IV significantly inhibited the levels of CCL5, MCP-1, IL-6 and IL-8. Astragaloside IV also reduced ICAM-1 expression for blocked THP-1 monocyte adhesion to BEAS-2B cells. Furthermore, astragaloside IV attenuated the phosphorylation of MAPK, and reduced the translocation of p65 into the nucleus. Astragaloside IV could increase the expression of HO-1 and Nrf2 for promoting the oxidant protective effect. Conclusion: Aastragaloside IV has an anti-inflammatory and oxidative effect via regulated NF-kappa B, MAPK and HO-1/Nrf2 signalling pathways in human bronchial epithelial cells.

Automated summary

Astragaloside IV has anti-inflammatory and oxidative effects in human bronchial epithelial cells via regulation of NF-kappa B, MAPK, and HO-1/Nrf2 signaling pathways.